Sustainable Strategies for Optimally Integrating FcRn Inhibitors into Individualized Treatment Paradigms for Generalized Myasthenia Gravis (gMG)
Sustainable Strategies for Optimally Integrating FcRn Inhibitors into Individualized Treatment Paradigms for Generalized Myasthenia Gravis (gMG)
Decision Tree
No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Recent data reveal that patients with gMG treated with older therapies often express negative sentiment towards MG symptoms, particularly fear, and desire treatments that offer symptom control, convenience, and flexibility, highlighting the need for improved therapeutic decision-making. The advent of novel neonatal Fc receptor (FcRn) inhibitors has shifted the treatment paradigm to address these unmet needs, increasing the potential for patients to achieve minimal manifestation status and reducing the burden of disease.
To help you adeptly navigate the complexities of treatment, immerse yourself in this interactive “choose your path” decision tree and supporting practice compendium with expert perspectives to assist with the application of the latest evidence to individualize therapy for this “snowflake” disease.
Do you have questions about how to individualize treatment and when to use FcRn inhibitors? Do you wonder…
- How to recognize patients who are refractory to conventional treatments?
- Does age of disease onset matter? What about patient comorbidities?
- How does disease severity inform first-line therapy and the integration of novel treatments?
- How do factors such as dosing frequency, route of administration, and patient preference weigh on treatment selection?
- How the mechanisms of action of the FcRn inhibitors differ, and how they impact patient QoL?
Start your engaging learning experience now and find the answers to these questions and more!
Faculty: James F. Howard Jr, MD, Neelam Goyal, MD
Release Date:
Expiration Date: August 29, 2026
